Development of systemic sarcoidosis and xanthoma planum during multiple sclerosis treatment with interferon‐beta 1a: Case Report

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-4632|54|5|e140-e145

ISSN： 0011-9059

Source： INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol.54, Iss.5, 2015-05, pp. : e140-e145

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antibodies to Commercially Available Interferon–Beta Molecules in Multiple Sclerosis Patients Treated with Natural Interferon–Beta

By  

International Archives of Allergy and Immunology, Vol. 118, Iss. 2-4, 1999-04 ,pp. : 368-371

Karger

Access to resources Recommend Favorite

Interferon-β treatment associated with a biochemical profile suggestive of acromegaly. A case report of a patient treated for multiple sclerosis

By Andreassen Mikkel   Frystyk Jan   Miller Karen K   Kristensen Lars Ø  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 70, Iss. 7, 2010-11 ,pp. : 519-522

Informa Healthcare

Access to resources Recommend Favorite

Interferon beta‐1b‐induced Sweet's syndrome in a patient with multiple sclerosis

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 4, 2015-04 ,pp. : 456-458

John Wiley & Sons Inc

Access to resources Recommend Favorite

Glatiramer acetate versus interferon Beta-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients

By Castelli-Haley Jane  

Advances in Therapy, Vol. 25, Iss. 8, 2008-08 ,pp. : 830-830

Springer Publishing Company

Access to resources Recommend Favorite

Exacerbation of Darier disease by peg‐interferon beta‐1a in a patient suffering from multiple sclerosis

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 57, Iss. 1, 2018-01 ,pp. : 116-117

John Wiley & Sons Inc

Access to resources Recommend Favorite